Onconetix, Inc. (ONCO) stock
Close on Nov 12, 2026Market cap $11.97MP/E –Yield –
Onconetix, Inc. saw revenue fall 51.3% to $645.82K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $11.97M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.97M
- P/E ratio
- –
- Price to sales
- 18.53
- Price to book
- 0.89
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $645.82K
- Net income
- -$10.20M
- EPS, diluted
- -$16.56
- Book value per share
- $6.01
- Diluted shares
- 2M
Trading
- Previous close
- $3.76
- Open
- $3.58
- Day's range
- $2.94 – $3.58
- Volume
- 92,045
- Average volume (20 days)
- 411,173
- Beta (5 years)
- 4.78
- 52-week range
- $0.53 – $1610.00
- RSI (14 days)
- 45.6
- Volatility (1 year)
- 5083.2%
- Relative volume
- 0.11×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ONCO | S&P 500 | Difference | ONCO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -48.7% | -2.7% | −46.0 pts | ||
| 3 months | -66.0% | -1.7% | −64.3 pts | ||
| Year to date | -99.6% | +11.9% | −111.5 pts | ||
| 1 year | -99.8% | +12.0% | −111.8 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -98.2% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -78.9% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -54.1% | +15.1% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Onconetix filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- News
- News
About Onconetix
Pharmaceutical Preparations
Onconetix, Inc. is a commercial-stage biotechnology enterprise specializing in the research, development, and commercialization of solutions for men’s health and oncology. The company focuses primarily on Proclarix, an in vitro protein-based diagnostic blood test for prostate cancer that assesses risk to help determine the necessity of patient biopsies following inconclusive prostate-specific antigen results. While previously developing treatments such as a daily combination therapy for benign prostatic hyperplasia, the organization has discontinued those initiatives to concentrate on its core oncology diagnostic asset. Target end users include physicians, patients, and local diagnostic laboratories.
Company profile, executives and historyOnconetix stock: common questions
What is Onconetix's stock price?
ONCO closed at $3.03 on Nov 12, 2026, down 19.41% on the day. Over the past 52 weeks it traded between $0.53 and $1610.00.
What is Onconetix's market cap?
Onconetix was worth $11.97M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ONCO's P/E ratio?
Onconetix lost money over fiscal 2025 (diluted EPS -$16.56), so it has no meaningful P/E ratio.
How much revenue does Onconetix make?
Onconetix reported revenue of $645.82K for the twelve months to Jun 30, 2026, down 51.3% from a year earlier.
Does Onconetix pay a dividend?
No. Onconetix has not paid a cash dividend over the last twelve months.
How has ONCO stock performed over the past year?
Including dividends, ONCO returned -99.8% over the past year, against +12.0% for the S&P 500.
How many ONCO shares are sold short?
1M shares were sold short at the latest FINRA report, 40.63% of the float, or 1.0 days of average trading volume.
Who are Onconetix's competitors?
Companies most similar to Onconetix by business, industry and size include QUCY, VCNX, XCUR, RFL, YARW.
See a number that looks wrong?